leadf
logo-loader
viewNovaBay Pharmaceuticals

NovaBay Pharmaceuticals delivers positive results for two anti-microbial drug studies

NovaBay's Aganocide compounds are anti-microbial compounds designed to mimic the body's natural defense against infection

test tubes
NovaBay has a license and research collaboration agreement with Alcon

Biotech company NovaBay Pharmaceuticals (NYSE Amex:NBY) said Monday that data from two separate studies for the company's Aganocide compounds delivered "compelling" results against impetigo, a bacterial infection of the skin, and nail fungus infection, respectively.

NovaBay's Aganocide compounds are anti-microbial compounds designed to mimic the body's natural defense against infection. The compounds are currently being studied in both preclinical and clinical programs, and have the potential to address the growing problem of antibiotic resistance, said the company.

The first study by NovaBay was designed to evaluate the efficacy and safety of three different strengths of NVC-422 Topical Gel in the treatment of impetigo.

Impetigo is a highly contagious superficial bacterial infection of the skin that affects mostly children, and multi-drug resistant strains such as MRSA are being observed with increasing frequency in this population.

129 children ranging from 2-12 years of age were tested, and clinical and bacteriological response rates for the three concentrations ranged from 84% to 95% at the end of treatment and at follow up. Notably, response rates for MRSA infections were 100% across all treatment groups, said NovaBay.

During the second study, NVC-422 was tested to work against onychomycosis, a commonly diagnosed nail disorder. Topical treatment of the infection is currently limited, as available drugs fail to penetrate the human nail.

The new trial was conducted using an in vitro-infected human nail model, and showed that NVC-422 gel formulations could in fact penetrate and kill fungi grown on the subungal side of the infected nail.

NovaBay has a license and research collaboration agreement with Alcon for use of its Aganocide compounds to treat eye, ear and sinus infections, as well as for contact lens care. The company has also entered into a deal with Galderma to develop and commercialize Aganocide compounds in impetigo and other dermatological indications.

The company was up more than 1.5% on Monday, trading at $1.94 at 12:12pm ET.

Quick facts: NovaBay Pharmaceuticals

Price: 0.7283 USD

NYSEMKT:NBY
Market: NYSEMKT
Market Cap: $30.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Lotus Resources reveals highlights on scoping study at its Kayelekera...

Lotus Resources Ltd (ASX:LOT) Managing Director Eduard Smirnov tells Proactive the group's Kayelekera Uranium Project can be among first uranium projects to begin production to meet the impending uranium supply shortfall. Smirnov says according to the study, the project will have a long mine...

10 hours, 50 minutes ago

2 min read